熱試験(Lutetium-177によるHER2抗体療法) (RAD202)
177LU-RAD202の安全性と忍容性の第0/1研究、進行性固形腫瘍患者のヒト表皮成長因子受容体2に対するルテチウム-177放射標識単一ドメイン抗体2
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
調査の概要
詳細な説明
This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation
- Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
- Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
- DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
- Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.
Safety Follow-Up Period:
- An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
- A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit
研究の種類
入学 (推定)
段階
- 初期フェーズ 1
連絡先と場所
研究連絡先
- 名前:Dimitris Voliotis, MD
- 電話番号:+1 646 535 5017
- メール:dv@radiopharmtheranostics.com
研究場所
-
-
New South Wales
-
Kingswood、New South Wales、オーストラリア、2747
- 募集
- Nepean Hospital
-
コンタクト:
- Veronica Wong, MD
- 電話番号:+61 2 4734 2156
- メール:Veronica.Wong@health.nsw.gov.au
-
Macquarie Park、New South Wales、オーストラリア、2109
- 募集
- Macquarie University Hospital
-
コンタクト:
- Dhanusha Sabanathan, MD
- 電話番号:+61 2 9812 3000
- メール:dhanusha.sabanathan@mqhealth.org.au
-
Wollongong、New South Wales、オーストラリア、2500
- 募集
- Wollongong Hospital
-
コンタクト:
- Udit Nindra, MD
- 電話番号:+61 2 4222 5200
- メール:udit.nindra@health.nsw.gov.au
-
-
Victoria
-
Fitzroy、Victoria、オーストラリア、3065
- 募集
- St Vincents Hospital, Melbourne
-
コンタクト:
- Melissa Moore, MD
- 電話番号:+61 3 9231 2211
- メール:melissa.moore@svha.org.au
-
-
Western Australia
-
Murdoch、Western Australia、オーストラリア、6150
- 募集
- GenesisCare Murdoch
-
コンタクト:
- Aviral Singh, MD
- 電話番号:+61 8 9366 1542
- メール:Aviral.Singh@genesiscare.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Aged 18 years and older.
-
Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.
-
Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.
Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).
-
Must have at least 1 measurable target lesion according to RECIST version 1.1.
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
-
Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.
-
Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
-
WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.
-
Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.
-
Participants with previously treated brain metastases are eligible to participate if:
- They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
- Do not require corticosteroids to treat associated neurological symptoms, and
- Participants have no history of leptomeningeal disease or spinal cord compression.
- Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.
Exclusion Criteria:
-
Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
-
Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.
-
Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy
-
Inadequate organ functions as reflected in laboratory parameters:
- Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
- Platelet count of < 80 x 109/L
- Absolute neutrophil count (ANC) < 1.5 x 109/L
- Haemoglobin < 9 g/dL
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
- Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
- For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
-
Significant cardiovascular disease including:
- Unstable angina and/or myocardial infarction within 6 months prior to screening
- New York Heart Association Class II or greater congestive heart failure
- Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
- QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
- Uncontrolled hypertension
- Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
-
History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity
-
Pregnant or lactating women
-
Participants who are receiving any other investigational agents
-
Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.
-
Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.
-
Positive status for human immunodeficiency virus (HIV).
-
Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.
-
Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.
-
Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:177Lu-RAD202
Single-arm, open-label study of 177Lu-RAD202 |
177Lu-RAD202 administered at treatment doses |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety and tolerability of 177Lu-RAD202
時間枠:6 weeks
|
The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
6 weeks
|
|
Recommended dose(s) of 177Lu-RAD202 for future exploration
時間枠:6 weeks
|
Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment |
6 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preliminary antitumor activity of 177Lu-RAD202
時間枠:Up to 30 weeks
|
Objective response rates (ORR) as assessed by RECIST v1.1 |
Up to 30 weeks
|
|
Time Activity Curves (TACs)
時間枠:72 hours
|
Percent of the injected activity vs time for selected organs and tumors |
72 hours
|
|
Radiation dosimetry of 177Lu-RAD202
時間枠:72 hours
|
Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow) |
72 hours
|
|
Pharmacokinetics of 177Lu-RAD202
時間枠:72 hours
|
Half-life of 177Lu-RAD202 in blood |
72 hours
|
|
Biokinetics of 177Lu-RAD202
時間枠:72 hours
|
Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions |
72 hours
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
時間枠:Up to 30 weeks
|
Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT |
Up to 30 weeks
|
|
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
時間枠:Up to 30 weeks
|
Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow) |
Up to 30 weeks
|
|
Level of agreement between 177Lu-RAD202 and standard of care imaging
時間枠:Up to 30 weeks
|
Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone |
Up to 30 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。